Niche focus Target early-stage biotech partners and research groups focused on nanomedicine for virology and CNS disorders, highlighting Exavir’s ultra-long-acting integrase inhibitors as a specialized collaboration or co-development opportunity.

Strategic partnerships Position Exavir as a potential collaborator for larger pharma companies seeking to augment their HIV treatment and PrEP portfolios with novel long-acting formulations, offering shared IP development and risk-sharing models.

Clinical leverage Emphasize opportunities to engage clinical networks and academic consortia studying chronic HIV management and CNS infections, leveraging Exavir’s focus to accelerate proof-of-concept studies and translational research.

Funding readiness Highlight potential for grant-supported programs and non-dilutive funding avenues aimed at innovative nanomedicine approaches, appealing to partners seeking validated, government-aligned R&D opportunities.

Early-stage advantage Leverage the small team size and startup agility to propose quick-withdraw/exit-scenarios, pilot collaborations, and rapid milestone-driven deals that can de-risk larger-scale partnerships with bigger incumbents.